{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:29:32Z","timestamp":1765826972525},"reference-count":33,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1507\/endocrj.k10e-407","type":"journal-article","created":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T05:20:18Z","timestamp":1303881618000},"page":"475-484","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD)"],"prefix":"10.1507","volume":"58","author":[{"given":"Sang Hoon","family":"Han","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialun","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneeta","family":"Saghayam","sequence":"additional","affiliation":[{"name":"YRG Centre for AIDS Research and Education, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasheela","family":"Vanar","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Malaya, Lembah Pantai, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[{"name":"Thai Red Cross AIDS Research Centre, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming A","family":"Chen","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital and AIDS Prevention and Research Centre, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thira","family":"Sirisanthana","sequence":"additional","affiliation":[{"name":"Research Institute for Health Sciences, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somnuek","family":"Sungkanuparph","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher KC","family":"Lee","sequence":"additional","affiliation":[{"name":"Hospital Sungai Buloh, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Pujari","sequence":"additional","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick CK","family":"Li","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[{"name":"National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vonthanak","family":"Saphonn","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Dermatology & STDs, Phnom Penh, Cambodia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuti Parwati","family":"Merati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G","family":"Law","sequence":"additional","affiliation":[{"name":"National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Carr A, Cooper DA (1998) Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. <i>N Engl J Med<\/i> 339: 1296.","DOI":"10.1056\/NEJM199810293391806"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041811"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, Ngeth C, Ferradini L, Delfraissy JF, Laureillard D (2008) Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. <i>Antivir Ther<\/i> 13: 697-703.","DOI":"10.1177\/135965350801300509"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fernandes AP, Sanches RS, Mill J, Lucy D, Palha PF, Dalri MC (2007) Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: considerations for psychosocial aspects. <i>Rev Lat Am Enfermagem<\/i> 15: 1041-1045.","DOI":"10.1590\/S0104-11692007000500024"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zhou J, Paton NI, Ditangco R, Chen YM, Kamarulzaman A, Kumarasamy N, Lee CK, Li PC, Merati TP, Phanuphak P, Pujari S, Vibhagool A, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG (2007) Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. <i>HIV Med<\/i> 8: 8-16.","DOI":"10.1111\/j.1468-1293.2007.00417.x"},{"key":"6","unstructured":"6. Wohl DA, Brown TT (2008) Management of morphologic changes associated with antiretroviral use in HIV-infected patients. <i>J Acquir Immune Defic Syndr<\/i> 49 Suppl 2: S93-S100."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Asensi V, Rego C, Montes AH, Collazos J, Carton JA, Castro MG, Alvarez V, Fernandez C, Maradona JA, Valle-Garay E (2008) IL-1beta (+3954C\/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. <i>Genet Med<\/i> 10: 215-223.","DOI":"10.1097\/GIM.0b013e3181632713"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bonnet E, Bernard J, Fauvel J, Massip P, Ruidavets JB, Perret B (2008) Association of APOC3 polymorphisms with both dyslipidemia and lipoatrophy in HAART-receiving patients. <i>AIDS Res Hum Retroviruses<\/i> 24: 169-171.","DOI":"10.1089\/aid.2007.0076"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Guallar JP, Gallego-Escuredo JM, Domingo JC, Alegre M, Fontdevila J, Martinez E, Hammond EL, Domingo P, Giralt M, Villarroya F (2008) Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. <i>AIDS<\/i> 22: 575-584.","DOI":"10.1097\/QAD.0b013e3282f56b40"},{"key":"10","unstructured":"10. UNAIDS\/WHO: 2008 Report on the global HIV\/AIDS epidemic. The Joint United Nations Programme on HIV\/AIDS page. Available at: http:\/\/www.unaids.org\/en\/KnowledgeCentre\/HIVData\/ GlobalReport\/2008\/2008_Global_report.asp Geneva Switzerland 2008."},{"key":"11","unstructured":"11. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S (2007) Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. <i>J Med Assoc Thai<\/i> 90: 452-458."},{"key":"12","unstructured":"12. Puttawong S, Prasithsirikul W, Vadcharavivad S (2004) Prevalence of lipodystrophy in Thai-HIV infected patients. <i>J Med Assoc Thai<\/i> 87: 605-611."},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1086\/344055"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0924"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, Paton NI, Phanuphak P, Pujari S, Vibhagool A, Wong WW, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. <i>J Acquir Immune Defic Syndr<\/i> 38: 174-179.","DOI":"10.1097\/01.qai.0000145351.96815.d5"},{"key":"16","unstructured":"16. Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep., 41, 1-19."},{"key":"17","unstructured":"17. The World Bank Group: Country Classification. 2006 Available at: http:\/\/web.worldbank.org\/WBSITE\/EXTERNAL\/ DATASTATISTICS\/0,,contentMDK:20420458~menuPK: 64133156~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html."},{"key":"18","unstructured":"18. US National Institutes of Health DAIDS HIV Vaccines and Research Program. National Institutes of Health. Division of AIDS (DAIDS) revised toxicity tables for grading the severity of adult and pediatric adverse events experiences, Version 1.0, December 2004, Washington. DC. Available at http:\/\/rsc.tech- res.com\/Document\/safetyandpharmacovigilance\/Table_for_ Grading_Severity_of_Adult_Pediatric_Adverse_Events.doc."},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020794"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M, Telenti A (2002) Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. <i>J Acquir Immune Defic Syndr<\/i> 31: 50-55.","DOI":"10.1097\/00126334-200209010-00007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA (2003) HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. <i>HIV Med<\/i> 4: 293-301.","DOI":"10.1046\/j.1468-1293.2003.00159.x"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00008"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pere D, Ignacio SL, Ramon T, Fernando L, Alberto T, Pompeyo V, Juan G, G MJ, Paloma G, Antonio V, Jaime C, Esteban R, Bernardino R, GA ML, Trinitario S, Ferran T, Juan Ramon L, Myriam G (2008) Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort. <i>Open AIDS J<\/i> 2: 26-38.","DOI":"10.2174\/1874613600802010026"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, Evison JM, Tarr PE, Schmid P, Perneger T, Hirschel B (2008) Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. <i>HIV Med<\/i> 9: 142-150.","DOI":"10.1111\/j.1468-1293.2007.00537.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mallal SA, John M, Moore CB, James IR, McKinnon EJ (2000) Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. <i>Aids<\/i> 14: 1309-1316.","DOI":"10.1097\/00002030-200007070-00002"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lichtenstein KA (2005) Redefining lipodystrophy syndrome: risks and impact on clinical decision making. <i>J Acquir Immune Defic Syndr<\/i> 39: 395-400.","DOI":"10.1097\/01.qai.0000167478.28051.3a"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832b4377"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.3.429"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Perez-Molina JA, Domingo P, Martinez E, Moreno S (2008) The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. <i>J Antimicrob Chemother<\/i> 62: 234-245.","DOI":"10.1093\/jac\/dkn191"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Dube MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P (2007) Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. <i>J Acquir Immune Defic Syndr<\/i> 45: 508-514.","DOI":"10.1097\/QAI.0b013e3181142d26"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccodato M, Noor MA, Giordano M (2006) Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. <i>Clin Infect Dis<\/i> 42: 273-280.","DOI":"10.1086\/498505"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. <i>J Infect Dis<\/i> 198: 234-240.","DOI":"10.1086\/589622"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, Lim PL (2007) Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). <i>AIDS Res Ther<\/i> 4: 18.","DOI":"10.1186\/1742-6405-4-18"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/58\/6\/58_K10E-407\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T13:56:14Z","timestamp":1686059774000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/58\/6\/58_K10E-407\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k10e-407","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}